In addition, a newly characterized monoclonal anti-LAG-3 antibody resulted in a significant delay in tumor growth when combined with PD-1 blockade in mice transplanted with colorectal cancer cells[163].These results suggest that the addition of anti-LAG-3 monoclonal antibodies might improve the response to currently used ICIs also in CRC. This evidence concerns the gene LAG3 and colorectal cancer.